KCT0001405招募中未知
A multicenter, randomized, placebo-controlled, double-blind, Phase III trial to evaluate the efficacy and safety of the fix-dose combination therapy with Gemigliptin 50mg and Rosuvastatin 20mg compared with each monotherapy in patients with type 2 diabetes and dyslipidemia
G Life Sciences0 个研究点目标入组 285 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 285
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1)Patient with type 2 Diabetes Mellitus and Dyslipidemia
- •2)Adults aged = 19 years old
排除标准
- •1)Patients with Type 1 Diabetes, Patients with Diabetic Ketoacidosis or Diabetic Coma as well as Pre-coma
- •2)Patients with Gestational Diabetes Mellitus or with Secondary Diabetes
- •3)Patients with NYHA Class III, IV Congestive Heart Failure or with Treatment-requiring Arrhythmia
- •4)Patients with Thyroid Dysfunction whose TSH is out of normal range with treatment
- •5)Patients with pituitary insufficiency or hypoadrenalism
研究者
相似试验
进行中（未招募）
不适用
A multicenter, randomized, placebo-controlled, double-blind study on the efficacy, safety and tolerability of Certican® in preventing end-stage renal disease (ESRD) in patients with autosomal dominant polycystic kidney disease (ADPKD) - ADPKDpolycystic kidney diseaseMedDRA version: 8.1Level: LLTClassification code 10011771Term: Cystic kidney diseaseEUCTR2006-001485-16-FRovartis Pharma GmbH300
进行中（未招募）
1 期
immunoglobulin infusion as adjuvant therapy in patients with Pemphigus VulgarisEUCTR2013-000211-24-DERuprecht-Karls-University Heidelberg10
进行中（未招募）
不适用
A multicenter, randomized, placebo-controlled, double-blind study on the efficacy, safety and tolerability of Certican® in preventing end-stage renal disease (ESRD) in patients with autosomal dominant polycystic kidney disease (ADPKD) - ADPKDEUCTR2006-001485-16-ATovartis Pharma GmbH300
进行中（未招募）
2 期
A study of JNJ-64042056 in participants with preclinical Alzheimer's diseasePreclinical Alzheimer’s DiseaseNervous System DiseasesISRCTN78730935Janssen-Cilag International NV498
进行中（未招募）
1 期
A pilot clinical trial with human alpha-1 antitrypsin in patients with chronic fatigue syndromePatients with chronic fatigue syndromeMedDRA version: 18.0Level: PTClassification code 10008874Term: Chronic fatigue syndromeSystem Organ Class: 10018065 - General disorders and administration site conditionsMedDRA version: 18.0Level: SOCClassification code 10018065Term: General disorders and administration site conditionsSystem Organ Class: 10018065 - General disorders and administration site conditionsEUCTR2014-002007-13-ESInstituto Grifols, S.A.26